Gene therapy for HCV/HBV-induced hepatocellular carcinoma

Current Opinion in Investigational Drugs

Volumn 11, Issue 12, 2010, Pages 1368-1377

  Smerdou, Cristian ^a   Menne, Stephan ^b   Hernandez Alcoceba, Ruben ^a   Gonzalez Aseguinolaza, Gloria ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B virus (HBV); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); preventive gene therapy; therapeutic gene therapy

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS C VACCINE; ONCOLYTIC VIRUS;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION REGULATION; GENE THERAPY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSTIMULATION; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE; REVIEW; TUMOR MICROENVIRONMENT; VACCINATION; VIRUS REPLICATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS;

EID: 79952766274     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Tsai WL, Chung RT: Viral hepatocarcinogenesis. Oncogene (2010) 29(16):2309-2324.
2. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer (2001) 37(Suppl 8): S4-S66.
3. Verme G, Brunetto MR, Oliveri F, Baldi M, Forzani B, Piantino P, Ponzetto A, Bonino F: Role of hepatitis δ virus infection in hepatocellular carcinoma. Dig Dis Sci (1991) 36(8):1134-1136.
4. García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, Soriano V: Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol (2001) 96(1):179-183. (Pubitemid 32104826)
5. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM: Hepatocellular carcinoma: Novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 61: 317-328.
6. Vullierme MP, Paradis V, Chirica M, Castaing D, Belghiti J, Soubrane O, Barbare JC, Farges O: Hepatocellular carcinoma-What's new? J Visc Surg (2010) 147(1):1-12.
7. Chin L, Gray JW: Translating insights from the cancer genome into clinical practice. Nature (2008) 452(7187):553-563. (Pubitemid 351483369)
8. Feitelson MA, Lee J: Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett (2007) 252(2): 157-170. (Pubitemid 46809787)
9. Cougot D, Neuveut C, Buendia MA: HBV induced carcinogenesis. J Clin Virol (2005) 34(Suppl 1):S75-S78.
10. Bouchard MJ, Wang L, Schneider RJ: Activation of focal adhesion kinase by hepatitis B virus HBx protein: Multiple functions in viral replication. J Virol (2006) 80(9):4406-4414.
11. Klein NP, Schneider RJ: Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol Cell Biol (1997) 17(11):6427-6436. (Pubitemid 27451188)
12. Hildt E, Hofschneider PH: The PreS2 activators of the hepatitis B virus: Activators of tumour promoter pathways. Recent Results Cancer Res (1998) 154:315-329.
13. Castello G, Scala S, Palmieri G, Curley SA, Izzo F: HCV-related hepatocellular carcinoma: From chronic infammation to cancer. Clin Immunol (2010) 134(3):237-250.
14. Koike K, Moriya K, Matsuura Y: Animal models for hepatitis C and related liver disease. Hepatol Res (2010) 40(1):69-82.
15. Li Y, Wan D, Wei W, Su J, Cao J, Qiu X, Ou C, Ban K, Yang C, Yue H: Candidate genes responsible for human hepatocellular carcinoma identifed from differentially expressed genes in hepatocarcinogenesis of the tree shrew (Tupaia belangeri chinesis). Hepatol Res (2008) 38(1):85-95. (Pubitemid 350182580)
16. Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, Schinazi RD, Korba BE, Cote PJ, Gerin JL: Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology (2004) 127 (Suppl 1):S283-S293. (Pubitemid 39423398)
17. Transy C, Fourel G, Robinson WS, Tiollais P, Marion PL, Buendia MA: Frequent amplifcation of c-MYC in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. Proc Natl Acad Sci USA (1992) 89(9):3874-3878.
18. Seeger C, Baldwin B, Hornbuckle WE, Yeager AE, Tennant BC, Cote P, Ferrell L, Ganem D, Varmus HE: Woodchuck hepatitis virus is a more effcient oncogenic agent than ground squirrel hepatitis virus in a common host. J Virol (1991) 65(4): 1673-1679.
19. Amako Y, Tsukiyama-Kohara K, Katsume A, Hirata Y, Sekiguchi S, Tobita Y, Hayashi Y, Hishima T, Funata N, Yonekawa H, Kohara M: Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J Virol (2010) 84(1):303-311.
20. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM: Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest (2010) 120(3):924-930.
21. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4(9):1065-1067. (Pubitemid 28417341)
22. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML: Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology (2004) 40(4):874-882. (Pubitemid 39288120)
23. Scott-Algara D, Mancini-Bourgine M, Fontaine H, Pol S, Michel ML: Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS One (2010) 5(1):e8761.
24. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G et al: Induction of antigen-specifc CD8+ T cells T helper cells and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine (2000) 19(7-8):764-778.
25. Roberts LK, Barr LJ, Fuller DH, McMahon CW, Leese PT, Jones S: Clinical safety and effcacy of a powdered hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine (2005) 23(40): 4867-4878. (Pubitemid 41242881)
26. Im SJ, Yang SH, Yoon SK, Sung YC: Increase of plasma IL-12/p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers. Immune Netw (2009) 9(1):20-26.
27. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3-and NS4A-specifc cellular immune responses induced in mice and rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 26(49): 6225-62231.
28. Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador-Cañizares Y, Helle F, Bédard N, Guerra I, Drouin C, Dubuisson J, González- Horta EE, Martínez G et al: Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepat (2009) 16(3):156-167.
29. Habersetzer F, Zarski JP, Leroy V, Maynard-Muet M, Bronowicki JP, Feray C, Hézode C, Fournillier A, Bain C, Inchauspé G, Honnet G et al: A novel vectorized HCV therapeutic vaccine (TG4040): Results of a phase I study in naïve patients chronically infected by HCV. J Hepatology (2009):50(Suppl 1): Abs 42.
30. Inchauspé G, Michel ML: Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat (2007) 14(Suppl 1):97-103. (Pubitemid 47624119)
31. Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B, Prince AM: Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant Vaccinia virus. J Virol (2008) 82(21):10896-10905. (Pubitemid 352691168)
32. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK: Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol (2010) 8(2):192-199.
33. Lim SG, Mohammed R, Yuen MF, Kao JH: Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol (2009) 24(8):1352-1357.
34. Tiemann K, Rossi JJ: RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1(3):142-151.
35. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA et al: Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology (2005) 41(6):1349-1356. (Pubitemid 40770288)
36. Trejo-Avila L, Elizondo-González R, Trujillo-Murillo Kdel C, Zapata-Benavides P, Rodríguez-Padilla C, Rivas-Estilla AM: Antiviral therapy: Inhibition of hepatitis C virus expression by RNA interference directed against the NS5B region of the viral genome. Ann Hepatol (2007) 6(3):174-180. (Pubitemid 350277196)
37. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA: Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 21(6): 639-644. (Pubitemid 36638090)
38. Uprichard SL, Boyd B, Althage A, Chisari FV: Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA (2005) 102(3):773-778. (Pubitemid 40282741)
39. Crowther C, Ely A, Hornby J, Mufamadi S, Salazar F, Marion P, Arbuthnot P: Effcient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modifed adenovirus vectors. Hum Gene Ther (2008) 19(11):1325-1331.
40. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 441(7092):537-541. (Pubitemid 44050158)
41. Kapadia SB, Brideau-Andersen A, Chisari FV: Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA (2003) 100(4):2014-2018. (Pubitemid 36254565)
42. Bode JG, Brenndörfer ED, Karthe J, Häussinger D: Interplay between host cell and hepatitis C virus in regulating viral replication. Biol Chem (2009) 390(10):1013-1032.
43. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P: Modulation of hepatitis C virus RNA abundance by a liver-specifc microRNA. Science (2005) 309(5740):1577-1581. (Pubitemid 41266486)
44. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2010) 327(5962):198-201.
45. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K: Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol (2009) 50(3):453-460.
46. Peng Z: Current status of Gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther (2005) 16:1016-1027. (Pubitemid 41324561)
47. Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P, Liu XH: Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 136(4):625-630.
48. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology (2009) 49(4):1098-1112.
49. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE: Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol (2008) 173(3):856-864.
50. Qian C, Bilbao R, Bruña O, Prieto J: Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology (1995) 22(1):118-123.
51. Bilbao R, Gérolami R, Bralet MP, Qian C, Tran PL, Tennant B, Prieto J, Bréchot C: Transduction effcacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: The woodchuck animal model. Cancer Gene Ther (2000) 7(5):657-662. (Pubitemid 30314049)
52. Gerolami R, Uch R, Faivre J, Garcia S, Hardwigsen J, Cardoso J, Mathieu S, Bagnis C, Brechot C, Mannoni P: Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol (2004) 40(2):291-297. (Pubitemid 38115835)
53. Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K, Tsujii T: Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology (1995) 22(6):1838-1846.
54. Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, Herrero I, Qian C, Benito A, Larrache J, Olagüe C, Boan J et al: A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther (2010) 17(12):837-843.
55. Guo ZS, Thorne SH, Bartlett DL: Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1785(2):217-231.
56. Russell SJ: RNA viruses as virotherapy agents. Cancer Gene Ther (2002) 9(12):961-966. (Pubitemid 35462559)
57. Altomonte J, Marozin S, Schmid RM, Ebert O: Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther (2010) 18(2): 275-284.
58. Mullen JT, Tanabe KK: Viral oncolysis for malignant liver tumors. Ann Surg Oncol (2003) 10(6):596-605. (Pubitemid 40486890)
59. Rein DT, Breidenbach M, Curiel DT: Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 2(1):137-143.
60. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral effcacy. Cell Res (2003) 13(6):481-489. (Pubitemid 43231842)
61. Su C, Peng L, Sham J, Wang X, Zhang Q, Chua D, Liu C, Cui Z, Xue H, Wu H, Yang Q et al: Immune gene-viral therapy with triplex effcacy mediated by oncolytic adenovirus carrying an interferon-gene yields effcient antitumor activity in immunodefcient and immunocompetent mice. Mol Ther (2006) 13(5):918-927.
62. Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong Y: Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery (2007) 141(4):520-529. (Pubitemid 46441313)
63. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D et al: Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther (2006) 14(3):361-370. (Pubitemid 44184970)
64. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, Sarraf C, Mitry R, Havlik R, Seth P, Hartwigsen J, Bhushan R et al: Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther (2002) 9(3):254-259. (Pubitemid 34205499)
65. Onyx Pharmaceuticals Inc: Onyx increases development focus on BAY 43-9006. Press Release (2003): January 27.
66. Liu TC, Hwang T, Park BH, Bell J, Kirn DH: The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 16(9):1637-1642.
67. Greten TF, Manns MP, Korangy F: Immunotherapy of hepatocellular carcinoma. J Hepatol (2006) 45(6):868-878. (Pubitemid 44646691)
68. Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fiedler M, Damen U, Tennant B, Scherer C, Graham FL et al: Large nontransplanted hepatocellular carcinoma in woodchucks: Treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J Natl Cancer Ins (2001) 93(6):472-479. (Pubitemid 32266540)
69. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olagüe C et al: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 22(8):1389-1397. (Pubitemid 41103620)
70. Rodriguez-Madoz JR, Liu KH, Quetglas JI, Ruiz-Guillen M, Otano I, Crettaz J, Butler SD, Bellezza CA, Dykes NL, Tennant BC, Prieto J et al: Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J Virol (2009) 83(23):12266-12278.
71. Sarin SK, Thakur V, Guptan RC, Saigal S, Malhotra V, Thyagarajan SP, Das BC: Profle of hepatocellular carcinoma in India: An insight into the possible etiologic associations. J Gastroenterol Hepatol (2001) 16(6):666-673. (Pubitemid 34188842)
72. Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK: Characteristics of hepatocellular carcinoma in India: A retrospective analysis of 191 cases. QJM (2008) 101(6): 479-485. (Pubitemid 351791532)
73. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z et al: Hepatitis C-related hepatocellular carcinoma in the United States: Infuence of ethnic status. Am J Gastroenterol (2003) 98(9):2060-2063. (Pubitemid 37185806)
74. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 27(9): 1485-1491.
75. Isvhld2006. Abstracts of the 12th international symposium on viral hepatitis and liver disease. J Clin Virol (2006) 75 (Suppl. 2): S4-S32.
76. ChronTech Pharma AB: Continued promising results from patients who have received standard of care treatment after vaccinations with ChronVac-C. Press Release (2010): October 25. chrontech.se/sv/press-och-nyheter/pressmeddelanden/? id=2010102520060
77. Hepatitis C virus (HCV) vaccines. Okairos, Rome, Italy (2010). www.okairos.it/e/inners.php?m=00046